Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Interferon alpha 2b suppository for cervical high-risk HPV infection
ChiCTR2100048075Phase 4Recruiting
- Sponsor
- The First Hospital of Jilin University
- Start
- Jul 2021
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised trial in human papillomavirus infection comparing Interferon alpha 2b suppository with Placebo suppository (2 arms). Primary endpoints: hr-HPV DNA clearance rate and hr-HPV DNA overall response rate. Started Jul 2021; status: recruiting.
02
Drugs
interferon alfa-2b
03
Conditions
human papillomavirus infection
Beyond the preview
Go deeper on ChiCTR2100048075.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100048075.